Suki AI

Suki Assistant listens to a patient encounter and turns it into a structured clinical note, staged orders, and patient instructions, plus ICD-10/HCC/CPT/E&M coding support. It's built and sold by Suki AI, Inc. (Redwood City, CA), founded and led by CEO Punit Soni; the company also sells the underlying speech and clinical-language model as 'Suki for Partners,' an API/SDK platform that other healthtech vendors (EHRs, telehealth, care-management, revenue-cycle products) embed into their own apps rather than Suki shipping a first-party product. That dual model — direct-to-clinician app plus white-label platform for other vendors — is the clearest structural difference from most ambient-scribe competitors, which mostly sell only the former. Partners publicly named include HealthEdge, Sevocity, Zoom, WellSky, Azalea Health, MEDENT and AvaSure (^[2], ^[8]).

Suki advertises 'deep, real-time' integration with four EHRs — Epic, Oracle Health, athenahealth and MEDITECH — with notes, orders and coding flowing back without copy-paste, plus narrower integrations with Azalea Health, MEDENT and Sevocity through named partnerships (^[1], ^[2]). The depth of that integration (what write-back actually covers — notes only, or notes plus orders plus coding, in your specific EHR build) is the detail that most determines day-one clinician adoption and is exactly the kind of thing that varies by health-system configuration rather than being uniform across the EHR as a whole. We could not verify integration depth beyond what Suki states on its own site; a buyer should get this confirmed against their own EHR instance before rollout, not assume the marketing page describes their build.

Suki has no public pricing page (suki.ai/pricing returns a 404); the site's only call to action is 'Contact Us' for a sales conversation. This is standard for enterprise ambient-documentation vendors selling into health systems — the comparable products (Nuance DAX Copilot, Abridge, Ambience) are similarly sales-led — but it means a buyer cannot compare cost per clinician or per encounter without engaging sales, and the listing has nothing to anchor on.

Suki states its platform is 'SOC2 Type 2 certified, and HIPAA compliant' with end-to-end encryption, repeated on both the marketing site and its partner developer documentation (^[1], ^[4]). It also operates a Vanta-hosted trust center at trust.suki.ai, which is consistent with holding a current SOC 2 report, but that page renders its control and certification list client-side and returned no content to a direct or proxied fetch, so we could not independently confirm the report's scope, auditor, or issue date — only that the trust center exists and the certification claim is made in multiple places. Buyers who need the actual SOC 2 report or its scope should request it directly rather than relying on the badge.

Suki's site cites an 81% increase in practice satisfaction, a 41% reduction in time spent on notes, a 60% reduction in feelings of burnout, a 48% reduction in amended encounters, and a $1,688 average increase in incremental monthly revenue per user ^[1]. These are Suki's own figures — the site does not name the studies, sample sizes, or methodology behind them, and we found no independent, peer-reviewed, or health-system-published validation of any of these numbers. Treat them as vendor claims about the product's effect, not as independently confirmed results.

Suki for Partners is a genuinely built-out developer product, not a marketing placeholder: public documentation at developer.suki.ai covers REST APIs and SDKs (Web, React/headless, iOS) across four workflows (ambient documentation, form filling, dictation, patient summaries), with a changelog, an RSS release feed, and a stated 2–4 week typical partner integration time versus 6–12 months to build the equivalent in-house (^[4], developer.suki.ai/updates/changelogs). This is a real strength for healthtech companies evaluating build-vs-buy for ambient AI, and it's unusually transparent documentation for a healthcare vendor.

Suki is backed by Venrock, First Round, Flare Capital Partners, March Capital, Hedosophia, and (per its investor logos) Philips Ventures and Zoom Ventures (^[7], ^[8]). We could not establish total funding raised or a current valuation from a primary source and are not publishing a figure. Recent product activity is frequent and substantive rather than roadmap talk: an 'Ask' clinical-decision-support feature built on Wolters Kluwer's UpToDate, launched October 8, 2026; a research initiative called 'Science at Suki,' launched September 10, 2026; recognition as a 'Transformational Innovation Leader in Ambient Clinical Intelligence' from Frost & Sullivan, announced September 1, 2026; and a nursing-focused consortium with health systems including McLeod Health, Citizens Memorial, Boone Health and Fisher-Titus, launched October 2025 (^[9], ^[8]).